The association of cannabis use on inpatient psychiatric hospital outcomes

References

• Wilkinson ST, Yarnell S, Radhakrishnan R, Ball SA, D’Souza DC. Marijuana legalization: impact on physicians and public health. Annu Rev Med 2016;67:453–466.
   PubMed Web of Science ®Google Scholar
• Lai HMX, Sitharthan T. Exploration of the comorbidity of cannabis use disorders and mental health disorders among inpatients presenting to all hospitals in New South Wales, Australia. Am J Drug Alcohol Abuse 2012;38:567–574.
   PubMed Web of Science ®Google Scholar
• Jouanjus E, Leymarie F, Tubery M, Lapeyre-Mestre M. Cannabis-related hospitalizations: unexpected serious events identified through hospital databases. Br J Clin Pharmacol 2011;71:758–765.
   PubMed Web of Science ®Google Scholar
• Schimmelmann BG, Conus P, Cotton S, Kupferschmid S, McGorry PD, Lambert M. Prevalence and impact of cannabis use disorders in adolescents with early onset first episode psychosis. Eur Psychiatry 2012;27:463–469.
   PubMed Web of Science ®Google Scholar
• Ksir C, Hart CL. Cannabis and psychosis: a critical overview of the relationship. Curr Psychiatry Rep 2016;18:1–11.
   PubMed Web of Science ®Google Scholar
• Tennant C. Marijuana and madness. Bull World Health Organiz 2005;83:479.
   Google Scholar
• Niemi-Pynttri JA, Sund R, Putkonen H, Vorma H, Wahlbeck K, Pirkola SP. Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 finnish inpatient cases. J Clin Psychiatry 2013;74:e94–99.
   PubMed Web of Science ®Google Scholar
• Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull 2016;42:1262–1269.
   PubMed Web of Science ®Google Scholar
• San L, Bernardo M, Gómez A, Peña M. Factors associated with relapse in patients with schizophrenia. Int J Psychiatry Clin Pract 2013;17:2–9.
   PubMed Web of Science ®Google Scholar
• Bergé D, Mané A, Salgado P, Cortizo R, Garnier C, Gomez L, et al. Predictors of relapse and functioning in first-episode psychosis: a two-year follow-up study. Psychiatry Serv 2016;67:227–233.
   PubMed Web of Science ®Google Scholar
• Fattore L. Synthetic cannabinoids-further evidence supporting the relationship between cannabinoids and psychosis. Biol Psychiatry 2016;79:539–548.
   PubMed Web of Science ®Google Scholar
• Sherif M, Radhakrishnan R, D’Souza DC, Ranganathan M. Human laboratory studies on cannabinoids and psychosis. Biol Psychiatry 2016;79:526–538.
   PubMed Web of Science ®Google Scholar
• Gage SH, Hickman M, Zammit S. Association between cannabis and psychosis: Epidemiologic evidence. Biol Psychiatry 2016;79:549–56.
   PubMed Web of Science ®Google Scholar
• Kim HS, Hall KE, Genco EK, Van Dyke M, Barker E, Monte AA. Marijuana tourism and emergency department visits in Colorado. N Engl J Med 2016;374:797–798.
   PubMed Web of Science ®Google Scholar
• Prince JD. Risk of inpatient stay for mental illness among individuals with substance use disorders. Psychiatry Serv. 2012;63:938–941.
   PubMed Web of Science ®Google Scholar
• Schubart CD, Boks MPM, Breetvelt EJ, van Gastel WA, Groenwold RHH, Ophoff RA, et al. Association between cannabis and psychiatric hospitalization. Acta Psychiatr Scand 2011;123:368–75.
   PubMed Web of Science ®Google Scholar
• Barbeito S, Vega P, Ruiz de Azúa S, Saenz M, Martinez-Cengotitabengoa M, González-Ortega I, et al. Cannabis use and involuntary admission may mediate long-term adherence in first-episode psychosis patients: a prospective longitudinal study. BioMed Cent Psychiatry 2013;13:326.
   Google Scholar
• Schoeler T, Petros N, Di Forti M, Klamerus E, Foglia E, Ajnakina O, et al. Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study. Lancet Psychiatry 2016;3:947–953.
   PubMed Web of Science ®Google Scholar
• Foti DJ, Kotov R, Guey LT, Bromet EJ. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry 2010;167:987–93.
   PubMed Web of Science ®Google Scholar
• Patel R, Wilson R, Jackson R, Ball M, Shetty H, Broadbent M, et al. Cannabis use and treatment resistance in first episode psychosis: a natural language processing study. Lancet (Lond Engl) 2015;385(Suppl):S79.
   PubMedGoogle Scholar
• Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction 1996;91:1585–614.
   PubMed Web of Science ®Google Scholar
• Childers SR, Breivogel CS. Cannabis and endogenous cannabinoid systems. Drug and Alcohol Depend 1998;51:73–87.
   PubMed Web of Science ®Google Scholar
• Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical Pharmacokinetics. 2003;42:327–60.
   PubMed Web of Science ®Google Scholar
• Sharma P, Murthy P, Bharath MMS. Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiatry 2012;7:149–56.
   PubMedGoogle Scholar
• Fraser AD, Worth D. Urinary excretion profiles of 11-nor-9-carboxy-9-tetrahydrocannabinol: a 9-THC-COOH to creatinine ratio study #2. Forensic Science International. 2003;133:26–31.
   PubMed Web of Science ®Google Scholar
• Smith-Kielland A, Skuterud B, Mørland J. Urinary excretion of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users. J Anal Toxicol 1999;23:323–332.
   PubMed Web of Science ®Google Scholar
• Huestis M a, Cone EJ. Differentiating new marijuana use from residual drug excretion in occasional marijuana users. J Anal Toxicol 1998;22:445–54.
   PubMed Web of Science ®Google Scholar
• Fraser AD, Worth D. Urinary excretion profiles of 11-nor-9-carboxy-delta9-tetrahydrocannabinol: a delta9-THCCOOH to creatinine ratio study. J Anal Toxicol 1999;23:531–534.
   PubMed Web of Science ®Google Scholar
• Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 2010;71:463–474.
   PubMed Web of Science ®Google Scholar
• Babatope T, Chotalia J, Elkhatib R, Mohite S, Shah J, Goddu S, et al. A Study of the impact of cannabis on doses of discharge antipsychotic medication in individuals with schizophrenia or schizoaffective disorder. Psychiatric Q 2016;87:729–733.
   PubMed Web of Science ®Google Scholar
• Johnson J, Wu C, Winder G, Casher M, Marshall V, Bostwick J. The effects of cannabis on inpatient agitation, aggression, and length of stay. J Dual Diagn. 2016;12:244–251.
   PubMed Web of Science ®Google Scholar
• Joynt KE, Jha AK. A path forward on medicare readmissions. N Engl J Med. 2013;368:1175–1177.
   PubMed Web of Science ®Google Scholar
• Glass D, Lisk C, J S. Refining the hospital readmissions reduction program. Medicare Payment Advisory Commission, Washington, DC;2012.
   Google Scholar
• Van Dijk D, Koeter MWJ, Hijman R, Kahn RS, Van den Brink W. Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study. Schizophr Res 2012;137:50–7.
   PubMed Web of Science ®Google Scholar
• Markus F, Leweke M, Kranaster L, Pahlisch F, Klosterko tter J, Hellmich M, et al. The efficacy of cannabidiol in the treatment of schizophrenia—a translational approach. Schizophrenia Bull 2011;37:313.
   Google Scholar
• Zuardi AW, Crippa JAS, Hallak JEC, Moreira FA, Guimarães FS. Cannabidiol, a cannabis sativa constituent, as an antipsychotic drug. Brazil J Med Biol Res 2006;39:421–9.
   PubMed Web of Science ®Google Scholar
• Schubart CD, Sommer IEC, van Gastel WA, Goetgebuer RL, Kahn RS, Boks MPM. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res 2011;130:216–21.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010;35:764–774.
   PubMed Web of Science ®Google Scholar
• Bradley CJ, Zarkin GA. Inpatient stays for patients diagnosed with severe psychiatric disorders and substance abuse. Health Serv Res 1996;31:387–408.
   PubMed Web of Science ®Google Scholar
• Wolff J, McCrone P, Patel A, Kaier K, Normann C. Predictors of length of stay in psychiatry: analyses of electronic medical records. BMC Psychiatry 2015;15:238.
   PubMed Web of Science ®Google Scholar